Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN PHARMACEUTICALS vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUVEN PHARMACEUTICALS   MYLAN
EQUITY SHARE DATA
    SUVEN PHARMACEUTICALS
Mar-23
MYLAN
Dec-18
SUVEN PHARMACEUTICALS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6293,967-   
Low Rs3882,184-   
Sales per share (Unadj.) Rs52.71,825.4-  
Earnings per share (Unadj.) Rs16.249.6-  
Cash flow per share (Unadj.) Rs18.0391.3-  
Dividends per share (Unadj.) Rs6.000-  
Avg Dividend yield %1.20-  
Book value per share (Unadj.) Rs68.21,974.7-  
Shares outstanding (eoy) m254.57514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x9.71.7 573.0%   
Avg P/E ratio x31.562.0 50.7%  
P/CF ratio (eoy) x28.27.9 358.7%  
Price / Book Value ratio x7.51.6 478.9%  
Dividend payout %37.10-   
Avg Mkt Cap Rs m129,3951,582,214 8.2%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m1,1050-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m13,403939,158 1.4%  
Other income Rs m4640-   
Total revenues Rs m13,867939,158 1.5%   
Gross profit Rs m5,739243,019 2.4%  
Depreciation Rs m477175,847 0.3%   
Interest Rs m12845,170 0.3%   
Profit before tax Rs m5,59722,002 25.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,484-3,500 -42.4%   
Profit after tax Rs m4,11325,502 16.1%  
Gross profit margin %42.825.9 165.5%  
Effective tax rate %26.5-15.9 -166.7%   
Net profit margin %30.72.7 1,130.1%  
BALANCE SHEET DATA
Current assets Rs m11,554524,425 2.2%   
Current liabilities Rs m3,031382,364 0.8%   
Net working cap to sales %63.615.1 420.4%  
Current ratio x3.81.4 277.9%  
Inventory Days Days14884 177.7%  
Debtors Days Days30293 323.8%  
Net fixed assets Rs m9,547182,181 5.2%   
Share capital Rs m255500 50.9%   
"Free" reserves Rs m17,0970-   
Net worth Rs m17,3521,015,998 1.7%   
Long term debt Rs m461,096,588 0.0%   
Total assets Rs m21,1012,725,301 0.8%  
Interest coverage x44.71.5 3,005.3%   
Debt to equity ratio x01.1 0.2%  
Sales to assets ratio x0.60.3 184.3%   
Return on assets %20.12.6 775.1%  
Return on equity %23.72.5 944.3%  
Return on capital %32.93.2 1,035.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m12,8240-   
CASH FLOW
From Operations Rs m4,509195,157 2.3%  
From Investments Rs m-1,948-100,875 1.9%  
From Financial Activity Rs m-2,358-90,916 2.6%  
Net Cashflow Rs m2021,617 12.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare SUVEN PHARMACEUTICALS With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUVEN PHARMACEUTICALS With: BERYL DRUGS  ZIM LABORATORIES  SANDU PHARMA  ANG LIFESCIENCES INDIA  FERMENTA BIOTECH  



Today's Market

Sensex Today Ends 487 Points Higher | Metal Stocks Shine | SBI & Axis Bank Zoom 5% Sensex Today Ends 487 Points Higher | Metal Stocks Shine | SBI & Axis Bank Zoom 5%(Closing)

After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.